NCT00574483 is a Phase 2 clinical trial of quinacrine in Renal Cell Carcinoma, sponsored by Cleveland BioLabs.

Who is sponsoring NCT00574483?

NCT00574483 is sponsored by Cleveland BioLabs.

What drugs are being tested in NCT00574483?

Interventions in NCT00574483: quinacrine.

What condition does NCT00574483 study?

NCT00574483 studies Renal Cell Carcinoma.

Is NCT00574483 still recruiting?

NCT00574483 is currently withdrawn. Last updated 31 July 2015.

Last reviewed 2015-07-31 · How we verify

NCT00574483

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma

Withdrawn Phase 2 Last updated 31 July 2015

What this trial tests

Phase 2 trial testing quinacrine in Renal Cell Carcinoma. Withdrawn.

Timeline

1 November 2007

Primary endpoint
1 January 2008

1 January 2008

Quick facts

Lead sponsor	Cleveland BioLabs
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 November 2007
Primary completion	1 January 2008
Estimated completion	1 January 2008
Sites	2 locations across United States

Drugs / interventions tested

quinacrine — full drug profile →

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Cleveland BioLabs

Who can join

18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Tumor response
Time frame: 6 months

Sponsor's own description

The overall response to standard therapies and to the newer antiangiogenesis therapies is not curative, and treatment-associated toxicities may be severe. Therefore, continued evaluation of therapies, with different mechanisms of action, is needed for patients with metastatic RCC.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.
Bryant J, Batis N, Franke AC, Clancey G, et al · · 2019 · cited 10× · PMID 31497252 · DOI 10.18632/oncotarget.27156
Repositioning Quinacrine Toward Treatment of Ovarian Cancer by Rational Combination With TRAIL.
Liang R, Yao Y, Wang G, Yue E, et al · · 2020 · cited 1× · PMID 32766144 · DOI 10.3389/fonc.2020.01118

Verify or expand the search:

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00574483 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cleveland BioLabs
Last refreshed: 31 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00574483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing